Page 78 - Read Online
P. 78
Page 8 of 8 Bilancini et al. Vessel Plus 2021;5:39 https://dx.doi.org/10.20517/2574-1209.2021.14
analysis. Adv Ther 2020;37:1013-33. DOI PubMed PMC
43. De Anna D, Mari F, Intini, S, Gasbarro V, Sortini A, et al. Effects of therapy with aminaftone on chronic venous and lymphatic stasis.
Minerva Cardioangiol 1989;37:251-4. PubMed
44. Ruaro B, Pizzorni C, Paolino S, Alessandri E, Sulli A. Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A
Feasibility Study. Front Pharmacol 2019;10:293. DOI PubMed PMC
45. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to
Scientific Evidence. Part I. Int Angiol 2018;37:181-254. DOI PubMed
46. Kakkos SK, Guex JJ, Lugli M, Nicolaides AN. CEAP clinical classes C0S-C4: differences, similarities and role of Ruscus + HMC +
vitamin C in patients with chronic venous disease. Int Angiol 2020;39:118-24. DOI PubMed
47. Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular
permeability induced by histamine in hamster cheek pouch. J Cardiovasc Pharmacol 1994;24:281-5. PubMed
48. Rauly-Lestienne I, Heusler P, Cussac D, Lantoine-Adam F, de Almeida Cyrino FZG, Bouskela E. Contribution of muscarinic receptors
to in vitro and in vivo effects of Ruscus extract. Microvasc Res 2017;114:1-11. DOI PubMed
